Stefan Faderl – författare

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials. Topics include: Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)Ras inhibitorsEpigenetic therapy (hypomethylaters and histone deacetylase inhibitors)Lenalidomide analogsNew chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesineCombinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)Thrombopoietic agentsLeukemias: Principles and Practice of Therapy Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory diseaseIncorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.

Topics include:

Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.

Topics include:

Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area